

Table of Contents

INTRODUCTION

About the Alaska

Tuberculosis Program Manual..... 1.2

Purpose 1.2

Audience 1.2

How to Use This Manual..... 1.3

Portable document format 1.3

Icons 1.3

Abbreviations 1.4

Purpose of Tuberculosis Control 1.7

Alaska Statutes and Regulations
on Tuberculosis Control 1.7

Objectives and Standards 1.8

Quality of care 1.8

National and state program objectives 1.8

National standards, guidelines and
recommendations 1.10

Roles, Responsibilities, and

Contact Information 1.11

State tuberculosis program staff 1.11

Local public health agencies 1.13

Private medical providers 1.13

Laboratories 1.14

Resources and References 1.15

Document retention 2.13

Genotyping.....2.14

Dissemination and Evaluation2.15

References2.16

TARGETED TESTING FOR LATENT TUBERCULOSIS INFECTION

Introduction.....3.2

Purpose 3.2

Policy 3.2

State laws and regulations 3.3

Tuberculosis Assessment / Screening of School Children3.4

High-Risk Groups3.5

When to Conduct Targeted Testing.....3.7

Approaches to increasing targeted testing
and treatment for latent tuberculosis infection..... 3.7

Screening for latent tuberculosis infection
in facilities 3.8

Alaska program standards for health care
facilities, staff and long-term care facilities 3.10

References3.12

B NOTIFICATIONS

Introduction.....4.2

Purpose 4.2

Pre-arrival medical screening for tuberculosis 4.2

Overseas screening of applicants for
immigration 4.4

Policy 4.6

Follow-up of B1 and B2 Tuberculosis Arrivals4.7

Division of Global Migration and Quarantine
forms 4.7

Electronic disease notification process
overview 4.7

Patient follow-up 4.8

SURVEILLANCE

Introduction 2.2

Purpose 2.2

Policy 2.5

State statutes and regulations 2.5

Reporting Tuberculosis 2.6

Reporting suspected or confirmed cases of
tuberculosis to the Section of Epidemiology 2.8

Tuberculosis case information to report to
the Alaska TB Program..... 2.10

Data Collection 2.12

Forms..... 2.12

Computerized tuberculosis registry 2.12

Evaluation of B1, B2, and B Tuberculosis Arrivals	4.10
Evaluation activities	4.10
Treatment	4.12
Resources and References	4.13

DIAGNOSIS OF TUBERCULOSIS DISEASE

Introduction	5.2
Purpose	5.2
Policy	5.3
Forms.....	5.3
Tuberculosis Classification System	5.4
High-Risk Groups	5.5
Case Finding	5.7
Identifying suspected tuberculosis cases	5.7
Follow-up on suspected cases of tuberculosis	5.9
Diagnosis of Tuberculosis Disease ...	5.11
Medical history.....	5.12
Human immunodeficiency virus screening	5.14
Physical examination	5.15
Tuberculin skin test and interferon gamma release assays.....	5.15
Chest radiography	5.16
Bacteriologic examination	5.17
Resources and References	5.20

TREATMENT OF TUBERCULOSIS DISEASE

Introduction	6.2
Purpose	6.2
Policy	6.2
Forms.....	6.3
Basic Treatment Principles	6.4
Treatment Regimens and Dosages	6.6
Regimens.....	6.6
Table 3: DRUG REGIMENS FOR MICROBIOLOGICALLY CONFIRMED PULMONARY TUBERCULOSIS CAUSED BY DRUG-SUSCEPTIBLE ORGANISMS	6.8

Dosages	6.9
Table 4: DOSES OF FIRST-LINE ANTITUBERCULOSIS DRUGS FOR ADULTS AND CHILDREN	6.10
Duration of treatment.....	6.12

Side Effects and Adverse Reactions

Basic monitoring steps	6.13
Reporting reactions	6.20
Monitoring for side effects and adverse reactions by anti-tuberculosis drug.....	6.20

Response to Treatment.....

Completion of Therapy

Figure 1: Management of Treatment Interruptions	6.23
---	------

Case Closing and End-of-Treatment Evaluation.....

Post-Treatment Evaluation

Treatment in Special Situations

Drug-resistant tuberculosis.....	6.27
Human immunodeficiency virus infection	6.28
Alcohol use disorder	6.30
Restarting anti-TB medications in patients with drug-induced hepatitis	6.31
Figure 3: Restarting Anti-TB Medications in Patients with Drug-induced Hepatitis.....	6.33
Liver disease	6.34
Renal insufficiency and end-stage renal disease	6.34
Tuberculosis associated with tumor necrosis factor-alpha antagonists	6.35
Culture-negative pulmonary tuberculosis	6.35
Extrapulmonary tuberculosis	6.36
Pregnancy and breastfeeding	6.37

Resources and References

Quick Guide to Important Tuberculosis Treatment Resources

Table 3: Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms	6.8
---	------------

Table 4: Doses of First-line Anti-tuberculosis Drugs for Adults and Children	6.10
---	-------------

Figure 1: Management of Treatment	
--	--

Interruptions.....	6.23
Figure 3: Restarting Anti-TB Medications in Patients with Drug-induced Hepatitis	6.33

DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION

Introduction	7.2
Purpose	7.2
Policy	7.2
Forms	7.2
Tuberculosis Classification System....	7.3
High-Risk Groups.....	7.4
Diagnosis of Latent Tuberculosis Infection.....	7.7
Mantoux tuberculin skin testing.....	7.8
Candidates for Mantoux tuberculin skin testing.....	7.9
Administration of the tuberculin skin test	7.12
Measurement of the tuberculin skin test	7.13
Interpretation of the tuberculin skin test.....	7.14
Interferon gamma release assays	7.16
Human immunodeficiency virus screening	7.17
Follow-up activities	7.17
Chest radiography	7.18
Chest X-ray interpretation and treatment.....	7.19
Work and school clearance	7.21
Resources and References.....	7.22

TREATMENT OF LATENT TUBERCULOSIS INFECTION

Introduction	8.2
Purpose	8.2
Policy	8.3
Forms.....	8.3
Whom to Treat	8.4
Window period prophylaxis for susceptible and vulnerable contacts.....	8.5
IGRA test results.....	8.6
Tuberculin skin test results of 5 mm or more.....	8.6

Tuberculin skin test results of 10 mm or more.....	8.6
Treatment Regimens and Dosages.....	8.6
Regimens	8.8
12-week Isoniazid-Rifapentine regimen	8.10
Obtaining/Administering Meds	8.10
Pyridoxine (Vitamin B6).....	8.11

Adverse Effects of Drugs Used to Treat LTBI..... 8.12

Reporting reactions	8.15
Monitoring for side effects and adverse reactions by anti-tuberculosis drug.....	8.17

Adherence

Monthly assessment of adherence.....	8.19
Directly observed therapy.....	8.19
Completion of Therapy	8.21

Treatment in Special Situations

Human immunodeficiency virus and latent tuberculosis infection	8.23
Alcohol Use Disorder.....	8.24
Pregnancy and breastfeeding	8.26
Resources and References.....	8.27

DIAGNOSIS AND TREATMENT OF LATENT TUBERCULOSIS INFECTION (LTBI) AND TUBERCULOSIS DISEASE IN CHILDREN (UNDER 16 YEARS OF AGE)

Introduction.....	9.2
Purpose	9.2
Background	9.3
Pathogenesis of tuberculosis	9.3

Latent Tuberculosis Infection (LTBI).... 9.5

Diagnosis of latent tuberculosis infection	9.5
Candidates for testing for tuberculosis infection .	9.5
Administration and interpretation of the TST	9.6
Interferon-Gamma release assays	9.8
BCG Vaccine.....	9.8
Management of children with a positive IGRA or TST	9.10

Treatment of Latent Tuberculosis Infection (LTBI)

.....	9.11
-------	------

LTBI treatment regimens and dosages.....	9.13	Cultural sensitivity and language issues	10.6
Dosages.....	9.14	Patient's medical records	10.7
Monitoring.....	9.15	Assessment site	10.8
Side effects and adverse reactions.....	9.15	Hospital discharge planning	10.8
Pyridoxine (Vitamin B6).....	9.15	Travel	10.11
Window Period prophylaxis	9.16	Initial assessment activities	10.12
Diagnosis of Tuberculosis Disease ...	9.18	Treatment Plan.....	10.17
Medical history.....	9.18	Treatment plan components.....	10.18
Physical examination	9.18	Planning activities.....	10.18
Radiology.....	9.19	Implementation activities	10.19
Bacteriologic testing.....	9.20	Ordering medication for the treatment of TB ..	10.21
Gastric aspirates.....	9.20	Ongoing Assessment	
Sputum collection	9.21	and Monitoring.....	10.23
Bronchoscopy	9.21	Ongoing assessment activities	10.23
Treatment of Tuberculosis.....	9.22	Monitoring side effects and	
Basic principles.....	9.22	adverse reactions	10.27
Treatment regimens and dosages.....	9.22	Activities to monitor for side effects and	
Regimens.....	9.22	adverse reactions	10.27
Duration of treatment.....	9.23	Monitoring bacteriologic improvement.....	10.28
First-line TB drugs	9.26	Activities to monitor for bacteriologic and	
Pharmacology and adverse reactions	9.27	clinical improvement.....	10.28
Monitoring response to treatment.....	9.28	Completion of Therapy	10.32
Medication side effects and adverse		Verifying adequate course of treatment	10.32
reactions.....	9.28	Calculating completion of therapy	10.32
Pyridoxine (Vitamin B6).....	9.28	Documenting completion of treatment and	
Response to treatment.....	9.29	follow-up recommendations	10.33
Completion of treatment	9.29	Case closures other than completion	
Special issues	9.30	of therapy	10.33
Isolation of children with tuberculosis disease...	9.30	Evaluation.....	10.35
Childcare and schools	9.30	Evaluation activities	10.35
Source case investigations	9.30	Directly Observed Therapy (DOT).....	10.37
Drug Delivery Options	9.31	Candidates for directly observed therapy	10.37
Resources and References	9.33	Face-to-face and video DOT	10.38
		How to deliver directly observed therapy	10.38
		Video Directly Observed Therapy (VDOT).....	10.39
		DOT Aides, regimens, and payment for DOT..	10.42
		Adherence to directly observed therapy.....	10.44
CASE MANAGEMENT		Incentives and Enablers	10.46
Introduction	10.2	Medical Orders.....	10.47
Purpose	10.2	Progressive interventions	10.47
Policy	10.3	Resources and References	10.48
Forms.....	10.4	Appendix	
TB case management timeline	10.5		
Initial Assessment.....	10.6		

***Latent Tuberculosis: A Quick Guide to
Case Management*.....A.1**

CONTACT INVESTIGATION

Introduction 11.2
 Purpose 11.2
 Policy 11.3
 Forms..... 11.4

**Structure of a
Contact Investigation**..... 11.5
 Basic steps of a contact investigation 11.5
 Contact investigation plan..... 11.5

**Decision to Initiate a
Contact Investigation**..... 11.6
 Factors predicting transmission
 of tuberculosis..... 11.6
 Deciding to initiate a contact investigation..... 11.8

**Time Frames for
Contact Investigation**..... 11.12
 Information about the index patient
 and transmission sites 11.12
 Contact evaluation and treatment..... 11.14
 Ongoing management activities 11.15

Infectious Period 11.17

Index Patient Interviews 11.19
 Pre-interview preparation..... 11.19
 General guidelines for interviewing
 an index patient 11.20

Field Investigation..... 11.21

Contact Priorities 11.23
 Index patient with positive acid-fast bacilli
 sputum smear results or cavitary tuberculosis 11.24
 Index patient with negative acid-fast bacilli
 sputum smear results 11.25
 Index patient with negative bacteriologic
 results and abnormal chest radiographs
 not consistent with tuberculosis 11.26

**Contact Evaluation, Treatment, and
Follow-up** 11.27
 Immunocompromised contacts
 and children under 5 11.28
 Immunocompetent adults and children 5 and older
 (high- and medium-priority contacts) 11.30

 Contacts with prior positive
 tuberculin skin tests 11.32

**When to Expand a
Contact Investigation** 11.34
 Guidelines for expanding an investigation..... 11.34
 Low-priority contacts 11.35

**Data Management and Evaluation
of Contact Investigations**..... 11.37
 Reasons contact investigation
 data are needed 11.37
 Index patient and contact data 11.39
 Evaluation of a contact investigation 11.41

Outbreak Investigation..... 11.42
 Definition of a tuberculosis outbreak 11.42
 Deoxyribonucleic acid genotyping 11.42

Resources and References 11.44

LABORATORY SERVICES

Introduction..... 12.2
 Purpose 12.2
 Policy 12.2

Laboratory Contact Information..... 12.3

Available Laboratory Tests..... 12.4

Specimen Collection 12.8
 How to perform spontaneous sputum
 collection at a healthcare facility..... 12.9
 How to direct a patient to perform
 spontaneous sputum collection at home 12.10
 Induced sputum collection at a
 healthcare facility..... 12.10
 How to collect gastric aspirates 12.11
 Bronchoscopy or collection of
 extrapulmonary specimens 12.11

Specimen Shipment 12.12

Resources and References 12.14

PATIENT EDUCATION

Introduction..... 13.2

Purpose	13.2
Policy	13.2
General Guidelines	13.4
Education Topics	13.5
Language and comprehension barriers	13.5
Medical diagnosis	13.6
Contact investigation	13.7
Isolation	13.7
Side effects and adverse reactions.....	13.7
Adherence	13.8
Patient Education Materials	13.9
Resources and References	13.10

CONFIDENTIALITY

Introduction	14.2
Purpose	14.2
Policy	14.2
Health Insurance Portability and Accountability Act (HIPAA).....	14.3
Centers for Disease Control and Prevention guidance on HIPAA	14.3
Alaska HIPAA policies	14.3
National Guidelines.....	14.4
Resources and References	14.5

TRANSFER NOTIFICATIONS

Introduction	15.2
Purpose	15.2
Policy	15.2
When to Initiate a Notification	15.4
How to Issue a Notification	15.5
Transfers in the U.S.....	15.5
Transfers outside the U.S.....	15.7
References	15.10

SUPPLIES AND SERVICES 16

INFECTION CONTROL

Introduction.....	17.2
Purpose	17.2
Policy.....	17.3
Hierarchy of Infection Control Measures	17.4
Administrative controls	17.4
Environmental controls.....	17.6
Personal respiratory protection	17.7
Who Should Use a Mask or Respirator	17.10
Employee Health.....	17.11
Two-Step tuberculin skin testing	17.11
Screening for persons with previously positive TST	17.14
Isolation	17.15
Estimating infectiousness.....	17.16
Determining noninfectiousness	17.16
Airborne Infection Isolation in a Healthcare Facility.....	17.18
When to initiate airborne infection isolation.....	17.19
When to discontinue airborne infection isolation	17.20
Hospital Discharge	17.22
Drug-susceptible tuberculosis disease	17.22
Multidrug-resistant tuberculosis disease	17.25
Release settings.....	17.25
Residential Settings	17.26
Administrative controls in the patient's home..	17.26
Environmental controls in the patient's home..	17.27
Respiratory protection in the patient's home ...	17.27
Other residential settings.....	17.28
Return to work, school, or other social settings.....	17.29
Tuberculosis Infection Control in Patient Care Facilities	17.31
Transportation Vehicles.....	17.33
Patient self-transport	17.33
Transport by healthcare workers.....	17.33
Transport by emergency medical services.....	17.33
Resources and References	17.34

FORMS 18

STATUTES AND REGULATIONS

Introduction 19.2
 Purpose..... 19.2
Conditions Reportable to Public
Health Manual..... 19.2
Regulations..... 19.3
 Infection Control 19.3
 Employee Health Programs 19.4
 School Screening 19.8
Resources and References..... 19.10

GLOSSARY 20